Picture of Connect Biopharma Holdings logo

CNTB Connect Biopharma Holdings Share Price

0.000.00%
us flag iconLast trade - 00:00
HealthcareSpeculativeSmall CapNeutral

Momentum

Relative Strength (%)
1m-19.72%
3m+3.02%
6m-23.67%
1yr+1.24%
Volume Change (%)
10d/3m-51.38%
Price vs... (%)
52w High-47.18%
50d MA0%
200d MA+26.79%

Growth & Value

Shareholder Activity

TypeBuy / Hold / Sell
Institutions
Directors
Community

Guru Screens

Quality

NameIndustryMarket
Return on Capital-61.08%
Return on Equity-46.03%
Operating Marginn/a

Health Trend(F-Score)

12345678910

Bankruptcy Score(Z-Score)

Distress
Cautious
Safe

Earnings Manipulation Risk(M-Score)

Other Ratios

Leverage (ttm)Total- Intang+ Pension
Gross Gearing
Net Gearing
Cash / Assets

Recent History

Latest interim period vs. prior periodIndustryMarket
Sales Growth
EPS Growth
3yr Compound Annual Growth RateIndustryMarket
Sales CAGR
EPS CAGR
DPS CAGR

Graphical History

Revenue
Blurred out image of Revenue chart
Net Income
Blurred out image of Net Income chart
Normalised EPS
Blurred out image of Normalised EPS chart
PE Ratio Range
Blurred out image of PE Ratio Range chart
Dividend Yield Range
Blurred out image of Dividend Yield Range chart

Analyst Forecasts

Price target
( price)
31st Dec 202431st Dec 2025
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change

Analyst Consensus

Strong SellSellHoldBuyStrong Buy

EPS 2024 / 2025

Blurred out image of Connect Biopharma Holdings EPS forecast chart

Profile Summary

Connect Biopharma Holdings Limited is a global clinical-stage biopharmaceutical company focused on improving the lives of patients with chronic inflammatory diseases through the development of therapies derived from T cell-driven research. It is building a pipeline of proprietary small molecules and antibodies, using functional T cell assays, to screen and discover potent product candidates against validated immune targets. Its lead product candidate, rademikibart, is an antibody designed to target interleukin-4 receptor alpha (IL-4Rα) in development for the treatment of atopic dermatitis (AD) and asthma. As an inhibitor of IL-4Rα, rademikibart blocks inflammatory signaling by both IL-4 and IL-13. Its second product candidate, icanbelimod, is a modulator of S1P1 T cell receptors and is in development for the treatment of ulcerative colitis (UC). Icanbelimod is an orally available, small molecule modulator of S1P1 that is designed to reduce inflammation without killing T cells.

Directors

    Last Annual
    December 31st, 2023
    Last Interim
    December 31st, 2023
    Incorporated
    November 23rd, 2015
    Public Since
    March 19th, 2021
    No. of Employees
    81
    Sector
    Biotechnology & Medical Research
    Industry
    Healthcare
    Exchange
    us flag iconNASDAQ Global Market
    Shares in Issue
    57,508,545

    CNTB Share Price Performance

    Upcoming Events for CNTB

    Similar to CNTB

    Picture of 89bio logo

    89bio

    us flag iconNASDAQ Global Market

    Picture of Abivax SA logo

    Abivax SA

    us flag iconNASDAQ Global Market

    Picture of AC Immune SA logo

    AC Immune SA

    us flag iconNASDAQ Global Market

    Picture of Acrivon Therapeutics logo

    Acrivon Therapeutics

    us flag iconNASDAQ Global Market

    Picture of Adagene logo

    Adagene

    us flag iconNASDAQ Global Market

    FAQ